Memory T-cells are a crucial component of the immune system that provides long-lasting protection against infections. After vaccination, the immune system not only produces antibodies but also activates T-cells that are responsible for recognizing infected cells. Some of these T-cells become memory T-cells, which "remember" the pathogen they were exposed to and remain in the body long-term. Upon re-exposure to the same pathogen, these memory T-cells quickly recognize the invader and mount an effective immune response. Vaccines aim to enhance this process by activating both the T-cell and B-cell arms of the immune system, ensuring long-term immunity. Memory T-cells are particularly important for preventing reinfection by pathogens like viruses, including the flu and COVID-19. They ensure that the immune system can respond more swiftly and effectively, even years after vaccination.
Duccio Medini
BioForge, United States
Jocelyn Jakubik
Apex Pathogen Solutions, United States
Sergey V Suchkov
N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Rosane Cuber Guimaraes
Bio-Manguinhos/ Fiocruz, Brazil
Aghapy Yermans Yakoup
Zewail City of Science and Technology, Egypt
Rosane Cuber Guimaraes
Bio-Manguinhos/ Fiocruz, Brazil
Zhujun Ao
University of Manitoba, Canada
K R Aneja
Kurukshetra University, India
Jocelyn Jakubik
Apex Pathogen Solutions, United States
Huanhuan Li
Queen’s University Belfast, United KingdomSubmit your abstract Today
Title : A universal AI design framework and brokerage platform for democratised manufacturing of mRNA therapeutics
Duccio Medini, BioForge, United States
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Development of VSV-vector based vaccine against H5N1 avian influenza by targeting both H5N1 hemagglutinin and matrix protein 2
Zhujun Ao, University of Manitoba, Canada
Title : A novel responsive microneedle platform for reliable drug and vaccine delivery
Huanhuan Li, Queen’s University Belfast, United Kingdom
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Comparative efficacy of different H9N2 avian influenza virus inactivated vaccines using some commercially available adjuvants for superior control in broilers
Ayman H M El Deeb, Cairo University, Egypt
Title : Structure-based design and development of next-generation Respiratory Syncytial Virus (RSV) vaccine
Lei Chen, Yikang Biotech Suzhou Co., Ltd, China
Title : Unmasking urban immunization inequities: A cross-sectional LQAS analysis of zero-dose drivers in slum and non-slum settings of Uttar Pradesh, India
Ashish Kumar Maurya, John Snow India, India